Compare Pudjiadi & Sons Tbk. (PNSE) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pudjiadi & Sons Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Pudjiadi & Sons Tbk. trades at Rp498 (market cap 398.91B, 4.1K 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Pudjiadi & Sons Tbk. is far larger — about 3.8× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| PNSE | SCPI | |
|---|---|---|
Market Cap | 398.91B | 104.4B |
Volume | 4.1K | — |
Lot | 41 | — |
Turnover | 2.01M | — |
Average Price | 490.93 | — |
Value | 2.01M | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pudjiadi & Sons Tbk.
PT Pudjiadi and Sons Tbk was established based on Notarial Deed No. 34 dated December 17, 1970 of Ridwan Suselo, s.h., notaris in Jakarta. Hotel business with all the facilities and infrastructures, such as , accommodation, office, shopping mall, apartment, recreation place and entertainment in the location of hotel. The Company is the owner of Jayakarta Hotel, a four star hotel.
Read more on PNSE →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
